Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.

Journal of thrombosis and haemostasis : JTH - 1 Dec 2015

Baumgartner C K, Zhang G, Kuether E L, Weiler H, Shi Q, Montgomery R R

Abstract excerpt

BACKGROUND: We have recently developed a successful gene therapy approach for hemophilia A in which factor VIII (FVIII) expression is targeted to platelets by the αIIb promoter. Levels of platelet-expressed FVIII (2bF8) achieved by gene therapy may vary between individuals due to differences in ex vivo transduction and gene expression efficiency. Accurate assays to evaluate 2bF8 efficacy are desirable. OBJECTIVE:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Blood Coagulation Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coagulants

Share to Dose-Response Relationship, Drug

Share to Factor VIII

Share to Kinetics

Share to Recombinant Proteins

Share to Thrombin

Source

Open in PubMed Open full text

Identifiers

PMID: 26453193
DOI: 10.1111/jth.13169
PMCID: PMC4715732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.PMID 26453193Read ↗

Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Semantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.Semantic proximity Read ↗

Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.Semantic proximity Read ↗

Improved Intrvenous Lentiviral Gene Therapy Based on Endothelial-specific Factor VIII for Hemophilia ASemantic proximity Read ↗

Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Semantic proximity Read ↗

Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.Semantic proximity Read ↗

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.Semantic proximity Read ↗

In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.Semantic proximity Read ↗

Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.Semantic proximity Read ↗

In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy.Semantic proximity Read ↗

Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.